Zolmit2.5 mg

Zolmit is FDA-approved for the acute treatment of migraine with or without aura in adults. It is used to relieve an ongoing migraine attack, not to reduce the number of attacks a patient has.

• Established/FDA-approved use: Acute (abortive) treatment of migraine headache once a migraine attack has already started.

Zolmit is not indicated for the prevention (prophylaxis) of migraine, and is not indicated for cluster headache, tension-type headache, or other headache types not clearly diagnosed as migraine. There is no well-established off-label use of Zolmit that is commonly recommended in guidelines.

Each tablet or orally disintegrating tablet of Zolmitriptan contains Zolmitriptan as the active pharmaceutical ingredient, commonly available in strengths of 2.5 mg. A nasal spray formulation of Zolmitriptan is also available, delivering 2.5 mg or 5 mg per spray. Excipients vary by manufacturer and formulation.

Zolmit is a second-generation triptan, a class of medicines used specifically for the acute treatment of migraine attacks. It works by binding selectively to serotonin (5-HT1B/1D) receptors in the brain and cranial blood vessels, leading to constriction of dilated blood vessels and reduction of the inflammatory signaling associated with migraine pain.

Zolmit is available as conventional tablets, orally disintegrating tablets (which dissolve on the tongue without water, useful for patients with migraine-associated nausea), and as a nasal spray for faster onset of action. It does not prevent migraine attacks and should be taken as soon as migraine symptoms begin for best effect.

Zolmit belongs to the triptan class of drugs, specifically classified as a selective serotonin 5-HT1B/1D receptor agonist. This class of anti-migraine agents also includes sumatriptan, rizatriptan, naratriptan, and eletriptan.

Zolmitriptan is a selective agonist at serotonin 5-HT1B and 5-HT1D receptors. Its therapeutic effect in migraine is believed to occur through three main mechanisms:

• Cranial vasoconstriction: Constriction of dilated intracranial extracerebral blood vessels that are thought to contribute to migraine pain.
• Inhibition of neuropeptide release: Reduced release of pro-inflammatory neuropeptides (such as CGRP) from trigeminal nerve endings.
• Reduced trigeminal nerve transmission: Decreased transmission of pain signals through the trigeminovascular pathway.

Zolmitriptan is well absorbed orally (bioavailability approximately 40%), with peak plasma concentration reached in about 1.5-2 hours. It is metabolized in the liver, partly to an active metabolite (N-desmethyl-zolmitriptan) that is more potent than the parent drug, and eliminated primarily via the kidneys. Its elimination half-life is approximately 2.5-3 hours.

Zolmit tablets are swallowed whole with water. Orally disintegrating tablets of Zolmit should be placed on the tongue, where they dissolve without the need for water, and can be taken by patients who have nausea or vomiting during a migraine attack. The nasal spray formulation of Zolmit is administered as a single spray into one nostril. Zolmit can be taken with or without food.

Zolmit has several well-documented, clinically significant drug interactions:

• Other triptans or ergotamine-type medicines (e.g., ergotamine, dihydroergotamine): Concurrent or recent (within 24 hours) use with Zolmit is contraindicated due to additive vasoconstrictive effects and increased risk of coronary vasospasm (see Contraindications).
• Monoamine oxidase-A (MAO-A) inhibitors: Concurrent use or use within 2 weeks of stopping an MAO-A inhibitor is contraindicated, as it significantly increases Zolmit plasma concentrations and toxicity risk.
• SSRIs and SNRIs: Concurrent use with Zolmit increases the risk of serotonin syndrome (a potentially life-threatening condition involving mental status changes, autonomic instability, and neuromuscular abnormalities). Monitor closely if co-administration is necessary.
• Cimetidine: Inhibits metabolism of Zolmit, approximately doubling its half-life and plasma levels; requires a lower Zolmit dose (see Dosage and Administration).
• Other CYP1A2 inhibitors (e.g., fluvoxamine, quinolone antibiotics): May similarly increase Zolmit exposure; use with caution.

Common side effects of Zolmit (occurring in approximately 5% or more of patients and more often than with placebo) include:

• Neck, throat, or jaw pain, tightness, or pressure
• Dizziness
• Paresthesia (tingling or numbness sensations)
• Somnolence (drowsiness)
• Asthenia (weakness)
• Sensations of warmth, cold, or heaviness
• Nausea
• Dry mouth

Serious but rare side effects include myocardial infarction, other cardiac arrhythmias, coronary artery vasospasm, stroke, serotonin syndrome (especially with concurrent SSRIs/SNRIs; see Interactions), and anaphylaxis/hypersensitivity reactions. Patients experiencing chest pain, severe dizziness, sudden weakness, or signs of an allergic reaction after taking Zolmit should seek immediate medical attention.

Pregnancy: There are limited data on the use of Zolmit in pregnant women. Animal studies have shown adverse effects (embryolethality and fetal structural abnormalities) at doses relevant to human exposure. Zolmit should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; consult a physician before use if pregnant or planning pregnancy.

Lactation: It is not known whether Zolmit passes into human breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted to weigh the benefits of treatment against the potential risk to a breastfeeding infant before using Zolmit while breastfeeding.

Zolmit should be used with caution in the following situations:

• Cardiovascular risk factors: Patients with risk factors for coronary artery disease (e.g., hypertension, diabetes, smoking, obesity, strong family history, postmenopausal women, men over 40) who do not meet the absolute contraindication criteria may warrant cardiac evaluation before first use of Zolmit, since serious cardiac events, though rare, have occurred with triptan use.
• Serotonin syndrome risk: Concurrent use of Zolmit with SSRIs or SNRIs increases the risk of serotonin syndrome (see Interactions); monitor for symptoms such as agitation, hallucinations, rapid heart rate, and muscle rigidity.
• Medication-overuse headache: Frequent use of Zolmit (generally more than 2-3 days per week) may lead to worsening headache patterns (medication-overuse headache). Limit frequency of use and consult a physician if headaches increase.
• Not for migraine prevention: Zolmit is intended only for acute treatment of an attack already in progress and is not effective for preventing migraine attacks.
• Hepatic impairment: Reduced dosing is required in moderate to severe hepatic impairment (see Dosage and Administration).

Limited experience with Zolmit overdose is available. Doses around 50 mg have commonly caused sedation. If an overdose of Zolmit is suspected, seek immediate medical attention or contact a poison control center. Management is supportive, with monitoring of cardiovascular status and vital signs for at least 15 hours or while symptoms persist, as the elimination half-life of Zolmit is prolonged compared to normal. There is no specific antidote for Zolmit overdose; it is not known whether hemodialysis or peritoneal dialysis is effective in removing it from the body.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly patients: Zolmit clearance is somewhat reduced with age; use with caution and screening for cardiovascular risk factors is recommended in older adults, particularly postmenopausal women and men over 40.

Renal impairment: No specific dose adjustment is generally required for mild to moderate renal impairment; Zolmit has not been studied in severe renal impairment, so caution is advised.

Hepatic impairment: Dose reduction of Zolmit is required in moderate to severe hepatic impairment (see Dosage and Administration).

Pediatric patients: See Pediatric Uses.

Zolmit is used on an as-needed basis for individual migraine attacks, not as a continuous daily treatment. A single dose is typically taken per attack, with a second dose permitted after at least 2 hours if needed, up to the maximum daily dose. Patients should limit use of Zolmit to no more than 2-3 days per week to avoid medication-overuse headache. If migraine attacks are frequent, a physician should be consulted regarding preventive (prophylactic) therapy, since Zolmit itself is not a preventive treatment.

Triptan; Selective serotonin 5-HT1B/1D receptor agonist; Anti-migraine agent

Zolmitriptan selectively activates 5-HT1B and 5-HT1D serotonin receptors located on cranial blood vessels and trigeminal sensory nerves. This produces vasoconstriction of dilated cranial vessels and inhibits the release of vasoactive, pro-inflammatory neuropeptides, thereby interrupting the pathological processes believed to underlie migraine pain.

C

The safety and efficacy of Zolmit in pediatric patients under 12 years of age have not been established. In adolescents aged 12 to 17 years, clinical trials of Zolmit nasal spray did not demonstrate a statistically significant difference in efficacy compared to placebo, so Zolmit is not currently recommended for use in this age group. Zolmit should not be used in children or adolescents unless specifically directed by a physician experienced in pediatric migraine management.